◆英語タイトル:Drugs for Neglected Diseases initiative - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014003
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月22日
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Drugs for Neglected Diseases initiative (DNDi) is a research center that discovers and develops new drugs. The center develops therapeutics for the treatment of various diseases. It offers treatments which include ASAQ, ASMQ, NECT, SSG&PM and pediatric benznidazole. DNDi also offers products for treatment of leishmaniasis, sleeping sickness, chagas disease, malaria, paediatric HIV and filarial diseases. The center also offers research programs for various organizations. It collaborates with private biotechnology industries, public institutions, academia and NGOs. The center operates in Switzerland, the US, Kenya, India, Brazil, Malaysia and Japan. DNDi is headquartered in Geneva, Switzerland.
Drugs for Neglected Diseases initiative – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Entasis Therapeutics and Global Antibiotic Research & Development Enter into Partnership 10
Optibrium Enters into Partnership with Imperial College London and DNDi 11
Daiichi Sankyo Enters into Research Agreement with Drugs for Neglected Diseases initiative 12
Institut Pasteur Korea Enters into Research Agreement with DNDi 13
DNDi Enters into Agreement with Takeda Pharma 14
Bayer HealthCare Enters into Co-Development Agreement with Drugs for Neglected Diseases Initiative 15
Institut Pasteur Korea and DNDi Enter into Research Agreement 16
Drugs for Neglected Diseases initiative Enters Into Agreement With Cipla To Develop Pediatric Antiretroviral Drug Combination 17
Astellas Pharma Enters Into Co-Development Agreement With DNDi For Neglected Diseases 18
DNDi Enters Into Co-Development Agreement With Abbott Labs For Neglected Tropical Diseases 19
Sanofi Enters Into Research Collaboration With DNDi 20
Drugs for Neglected Diseases initiative – Key Competitors 21
Drugs for Neglected Diseases initiative – Key Employees 22
Drugs for Neglected Diseases initiative – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Government and Public Interest 25
Jun 16, 2016: Epichem Successful in AusTrade Grant 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26
List of Tables
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Key Facts 2
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Drugs for Neglected Diseases initiative, Deals By Therapy Area, 2011 to YTD 2017 8
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Entasis Therapeutics and Global Antibiotic Research & Development Enter into Partnership 10
Optibrium Enters into Partnership with Imperial College London and DNDi 11
Daiichi Sankyo Enters into Research Agreement with Drugs for Neglected Diseases initiative 12
Institut Pasteur Korea Enters into Research Agreement with DNDi 13
DNDi Enters into Agreement with Takeda Pharma 14
Bayer HealthCare Enters into Co-Development Agreement with Drugs for Neglected Diseases Initiative 15
Institut Pasteur Korea and DNDi Enter into Research Agreement 16
Drugs for Neglected Diseases initiative Enters Into Agreement With Cipla To Develop Pediatric Antiretroviral Drug Combination 17
Astellas Pharma Enters Into Co-Development Agreement With DNDi For Neglected Diseases 18
DNDi Enters Into Co-Development Agreement With Abbott Labs For Neglected Tropical Diseases 19
Sanofi Enters Into Research Collaboration With DNDi 20
Drugs for Neglected Diseases initiative, Key Competitors 21
Drugs for Neglected Diseases initiative, Key Employees 22
Drugs for Neglected Diseases initiative, Other Locations 24